PRMB:NYSEPrimo Brands Corporation Analysis
Data as of 2026-04-25 - not real-time
$20.40
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Primo Brands is trading around $20.4, which is nearly double its DCF‑derived fair value of $11.2, implying a market premium of roughly 28% despite a trailing P/E of 97 and a forward P/E of 13. Revenue growth of 11% and a modest operating margin of 7% are being priced in, while the company carries a heavy debt load of $5.7 bn against just $0.38 bn in cash, yielding a debt‑to‑equity ratio above 190. Free cash flow remains positive at $0.44 bn, but the dividend payout ratio exceeds 190%, raising questions about the sustainability of the 2.35% yield. Recent news of a $3.09 bn refinancing term loan and an analyst upgrade to Buy with a $25 price target suggest improving capital structure and optimism on earnings momentum. Technically, the stock sits below its 20‑day SMA (19.56) and 50‑day SMA (19.93) but above the 200‑day SMA (20.86), with a bullish MACD histogram and an RSI near 56, indicating limited short‑term overbought pressure. However, volume trends are decreasing and the broader trend direction is flagged as bearish, with the price testing a support level around $17.88 and facing resistance near $21.33. High 30‑day volatility (~44%) and a beta of 0.65 point to moderate market sensitivity, while the max drawdown of over 56% underscores historical downside risk. The defensive consumer sector provides a cushion, but regulatory scrutiny on water quality and environmental standards adds a medium‑level risk. Overall, the stock appears priced for growth expectations that may be overstated given the balance‑sheet strain and dividend sustainability concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical trend with decreasing volume
- Current price above DCF fair value
- High valuation multiples (trailing P/E 97)
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Refinancing term loan improves balance‑sheet flexibility
- Analyst upgrade to Buy and price target of $25
- Forward P/E compression to 13 suggesting earnings upside
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Defensive consumer sector provides stability
- Sustainable cash flow but high debt burden
- Dividend payout ratio above earnings raises sustainability concerns
Key Metrics & Analysis
Financial Health
Revenue Growth11.20%
Profit Margin0.90%
P/E Ratio97.1
ROE2.50%
ROA4.09%
Debt/Equity191.31
P/B Ratio2.5
Op. Cash Flow$687.4M
Free Cash Flow$436.9M
Technical Analysis
TrendBearish
RSI55.9
Support$17.88
Resistance$21.33
MA 20$19.56
MA 50$19.93
MA 200$20.86
MACDBullish
VolumeDecreasing
Fear & Greed Index88.02
Valuation
Fair Value$11.21
Target Price$26.08
Upside/Downside27.86%
GradeOvervalued
TypeGrowth
Dividend Yield2.35%
Risk Assessment
Beta0.65
Volatility43.90%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.